HINT2 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the NCI-H1975 human lung adenocarcinoma epithelial cell line, engineered for disrupted function of the HINT2 gene. This polyclonal format provides a heterogeneous mixture of edited cells, enabling robust functional genomics studies without the isolation of a single clonal isolate. Loss of HINT2 is achieved through CRISPR/Cas9-mediated gene disruption, generating a powerful loss-of-function model for interrogating mitochondrial apoptosis regulation in cancer.
NCI-H1975 is a widely employed non-small cell lung cancer model harboring EGFR T790M and L858R mutations. These activating mutations confer sensitivity to second-generation EGFR tyrosine kinase inhibitors, and the cell line is frequently used to investigate mechanisms of acquired drug resistance and tumor progression. As a lung adenocarcinoma line with defined oncogenic drivers, it offers a clinically relevant background for studying the interplay between tumor suppressor pathways and EGFR signaling.
HINT2 encodes a pro-apoptotic mitochondrial protein that functions as a tumor suppressor by promoting mitochondrial calcium overload, cytochrome c release, and downstream caspase activation. Mechanistically, HINT2 interacts with MICU1, a regulator of the mitochondrial calcium uniporter (MCU) complex, to facilitate calcium entry into the mitochondrial matrix. This calcium influx triggers BAX/BAK-mediated permeabilization of the outer mitochondrial membrane, releasing cytochrome c and activating caspase-9, which in turn cleaves caspase-3 to execute apoptosis. HINT2 expression is controlled by p53-dependent transcription and is frequently silenced in cancer via promoter hypermethylation, linking DNA damage response and epigenetic regulation to mitochondrial cell death.
In the context of NCI-H1975 cells, HINT2 disruption abrogates a critical mitochondrial apoptosis effector, potentially enhancing cellular resistance to stress signals and EGFR-targeted therapies. This knockout model allows researchers to dissect how escape from mitochondrial apoptosis contributes to the malignant phenotype of EGFR-mutant lung adenocarcinoma, particularly under conditions of therapeutic pressure. By comparing wild-type and HINT2-knockout polyclonal populations, one can evaluate alterations in drug sensitivity, calcium handling, and apoptotic signaling.
This polyclonal knockout population is suited for a range of applications, including characterization of mitochondrial apoptosis regulators, epigenetic silencing of tumor suppressors, and combination therapy screenings. Representative assays include Western blotting for cleaved caspase-3, cytochrome c release assays, mitochondrial calcium imaging with Rhod-2, and MTT viability assays. The model facilitates investigation of p53-mediated apoptosis and the development of strategies to re-sensitize resistant cells. For additional information and technical support, please contact Ascent Research.
